Acoustic Characterization and Enhanced Ultrasound Imaging of Long‐Circulating Lipid‐Coated Microbubbles

Li, Hongbo; Yang, Yanye; Zhang, Meimei; Yin, Liangyu; Tu, Juan; Guo, Xiasheng; Zhang, Dong

doi:10.1002/jum.14470

Cited by 20 publications

(16 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sonovue is an ultrasound contrast agent that exhibits good biosafety and is widely used in clinical diagnosis. 35,36 The viability of cells in the experimental group was slightly lower than that of cells treated with Sonovue, although both were above 80%. The significantly lower cytotoxicity of RGD-Cy5.5-MBs according to the CCK8 results indicates their good biocompatibility.…”

Section: In Vitro Experiments With Rgd-cy55-mbsmentioning

confidence: 91%

<p>Dual-Mode Contrast Agents with RGD-Modified Polymer for Tumour-Targeted US/NIRF Imaging</p>

Nie¹,

Luo²,

Liu³

et al. 2020

OTT

View full text Add to dashboard Cite

Background Cancer diagnosis and treatment during the early stages of disease remain extremely challenging clinical tasks. The development of effective multimode contrast agents could greatly facilitate the early detection of cancer. Materials and Methods We prepared dual-mode contrast agents using a biotin/avidin bioamplification system. Through in vivo and in vitro experiments, we verified the imaging performance of this contrast agents in both fluorescence and ultrasound and its targeting specificity for MDA-MB-231 cells. Results The RGD peptide-labelled microbubbles showed excellent targeting of αvβ3 integrin expressed by MDA-MB-231 cells in vitro and in vivo. The signal intensity and time duration of ultrasound imaging using these particles were superior to those obtained with a typical ultrasound contrast agent in the clinic. The tumour areas also demonstrated high Cy5.5 accumulation by fluorescence imaging. Conclusion The results show that this targeted dual-mode imaging system yields outstanding US/NIRF imaging results, possibly allowing the early clinical diagnosis of cancer.

show abstract

Section: In Vitro Experiments With Rgd-cy55-mbsmentioning

confidence: 91%

<p>Dual-Mode Contrast Agents with RGD-Modified Polymer for Tumour-Targeted US/NIRF Imaging</p>

Nie¹,

Luo²,

Liu³

et al. 2020

OTT

View full text Add to dashboard Cite

show abstract

“…and sulfur hexafluoride (SF6), which have lower solubility in blood and thus increase the lifetime of the microbubbles in circulation. The shell could be albumin, phospholipid, polymeric or a combination of these materials [140,141]. The size of clinically approved UCAs is on the order of several microns and is small in comparison with the wavelength of diagnostic ultrasound (order 1 mm), meaning that bubbles are symmetrically driven and undergo volumetric oscillations in the absence of nearby boundaries or bubbles.…”

Section: Ultrasound Sensitive Substances: Ultrasound Contrast Agents (Ucas)mentioning

confidence: 99%

Photo- and Sono-Dynamic Therapy: A Review of Mechanisms and Considerations for Pharmacological Agents Used in Therapy Incorporating Light and Sound

Yang

et al. 2019

CPD

Self Cite

View full text Add to dashboard Cite

As irreplaceable energy sources of minimally invasive treatment, light and sound have, separately, laid solid foundations in their clinic applications. Constrained by the relatively shallow penetration depth of light, photodynamic therapy (PDT) typically involves involves superficial targets such as shallow seated skin conditions, head and neck cancers, eye disorders, early-stage cancer of esophagus, etc. For ultrasound-driven sonodynamic therapy (SDT), however, to various organs is facilitated by the superior... transmission and focusing ability of ultrasound in biological tissues, enabling multiple therapeutic applications including treating glioma, breast cancer, hematologic tumor and opening blood-brain-barrier (BBB). Considering the emergence of theranostics and precision therapy, these two classic energy sources and corresponding sensitizers are worth reevaluating. In this review, three typical therapies using light and sound as a trigger, PDT, SDT, and combined PDT and SDT are introduced. The therapeutic dynamics and current designs of pharmacological sensitizers involved in these therapies are presented. By introducing both the history of the field and the most up-to-date design strategies, this review provides a systemic summary on the development of PDT and SDT and fosters inspiration for researchers working on ‘multi-modal’ therapies involving light and sound.

show abstract

“…Microbubble shells can be composed of a variety of substances, including a surfactant (eg, SonoVue [Bracco SpA, Milan, Italy], Definity [Lantheus Medical Imaging, North Billerica, MA], and Sonazoid [GE Healthcare, Oslo, Norway]), silver nanoparticles, protein (eg, Albunex [Molecular Biosystems, San Diego, CA], CARDIOsphere [POINT Biomedical Corp, San Carlos, California], Optison [GE Healthcare]), a biopolymer (eg, ligands targeting vascular endothelial growth factor receptor [VEGFR], α v β 3 ‐integrin, and vascular cell adhesion molecule 1), galactose (eg, Echovist and Levovist [Schering AG, Berlin, Germany]), and polymers (eg, Acusphere [Acusphere Inc, Watertown, MA] and Sonovist [Schering AG]) . Microbubbles are often filled with varying gases such as air (eg, Levovist and Echovist), perflurobutane (eg, Sonazoid), perfluorohexane (eg, Imagent and Imavist [Alliance Pharmaceutical, San Diego, CA]), octafluoropropane (eg, Definity, Luminity [Lantheus Medical Imaging], and Optison), or sulfur hexafluoride (eg, Lumason [Bracco SpA] and SonoVue) . Most recent generations of microbubbles are smaller than 7 μm and can reach pulmonary and systemic capillaries.…”

Section: Number Of Primary Articles and Functions Of More Commonly Stmentioning

confidence: 99%

Scoping Review of Targeted Ultrasound Contrast Agents in the Detection of Angiogenesis

Lau¹,

Rivas²,

Dinalo

et al. 2019

J of Ultrasound Medicine

View full text Add to dashboard Cite

A systematic search was conducted to categorize targeted ultrasound contrast agents (UCAs) used in cancer-related angiogenesis detection. We identified 15 unique contrast agents from 2008 to March 2018. Most primary research articles studied UCAs targeted to vascular endothelial growth factor receptor or α v β 3 -integrin. Breast cancer and colon cancer are the most common neoplastic processes in which these agents were studied. BR55 (Bracco Research SA, Geneva, Switzerland), a vascular endothelial growth factor receptor-targeting UCA, is the first targeted UCA that has completed phase 0 trials. Our review identifies a gap in the literature regarding the application of targeted UCAs in cancer models beyond breast and colon cancers and identifies other promising UCAs.

show abstract

Acoustic Characterization and Enhanced Ultrasound Imaging of Long‐Circulating Lipid‐Coated Microbubbles

Cited by 20 publications

References 53 publications

<p>Dual-Mode Contrast Agents with RGD-Modified Polymer for Tumour-Targeted US/NIRF Imaging</p>

<p>Dual-Mode Contrast Agents with RGD-Modified Polymer for Tumour-Targeted US/NIRF Imaging</p>

Photo- and Sono-Dynamic Therapy: A Review of Mechanisms and Considerations for Pharmacological Agents Used in Therapy Incorporating Light and Sound

Scoping Review of Targeted Ultrasound Contrast Agents in the Detection of Angiogenesis

Contact Info

Product

Resources

About